BridgeBio Pharma (BBIO) Institutional Ownership
13F filers reported holding 54.8% of BridgeBio Pharma (BBIO) shares as of Sep 30, 2026, across 351 filers.
- Held by 13F filers
- 54.8%
- Sep 30, 2026
- 13F filers
- 351
- quarter ended Sep 30, 2026
- 13F value
- $7.0B
- 106.7M shares
- Quarter's fund flow
- Mild accumulation
- 50 new · 53 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Aug 19, 2026 | Kumar Neil | Chief Executive Officer | Disposed · Open-market sale | 8,100 | $83.86 | ↗ |
| Aug 19, 2026 | Kumar Neil | Chief Executive Officer | Disposed · Open-market sale | 1,800 | $84.69 | ↗ |
| Aug 19, 2026 | Kumar Neil | Chief Executive Officer | Disposed · Open-market sale | 100 | $85.65 | ↗ |
| Aug 18, 2026 | Kumar Neil | Chief Executive Officer | Disposed · Open-market sale | 1,900 | $81.15 | ↗ |
| Aug 18, 2026 | Kumar Neil | Chief Executive Officer | Disposed · Open-market sale | 17,279 | $82.21 | ↗ |
| Aug 18, 2026 | Kumar Neil | Chief Executive Officer | Disposed · Open-market sale | 14,602 | $82.99 | ↗ |
| Aug 18, 2026 | Kumar Neil | Chief Executive Officer | Disposed · Open-market sale | 1,199 | $83.77 | ↗ |
| Aug 16, 2026 | Trimarchi Thomas | President and CFO | Disposed · Tax withholding | 22,781 | $79.86 | ↗ |
| Aug 16, 2026 | Kumar Neil | Chief Executive Officer | Acquired · Option exercise | 33,544 | — | ↗ |
| Aug 16, 2026 | Kumar Neil | Chief Executive Officer | Acquired · Option exercise | 19,599 | — | ↗ |
| Aug 16, 2026 | Kumar Neil | Chief Executive Officer | Acquired · Option exercise | 11,554 | — | ↗ |
| Aug 16, 2026 | Kumar Neil | Chief Executive Officer | Acquired · Option exercise | 6,520 | — | ↗ |
| Aug 16, 2026 | Kumar Neil | Chief Executive Officer | Disposed · Tax withholding | 36,237 | $79.86 | ↗ |
| Aug 16, 2026 | Kumar Neil | Chief Executive Officer | Disposed · Option exercise | 33,544Restricted Stock Units | — | ↗ |
| Aug 16, 2026 | Kumar Neil | Chief Executive Officer | Disposed · Option exercise | 19,599Restricted Stock Units | — | ↗ |
| Aug 16, 2026 | Kumar Neil | Chief Executive Officer | Disposed · Option exercise | 11,554Restricted Stock Units | — | ↗ |
| Aug 16, 2026 | Kumar Neil | Chief Executive Officer | Disposed · Option exercise | 6,520Restricted Stock Units | — | ↗ |
| Aug 16, 2026 | Apuli Maricel | Chief Accounting Officer | Disposed · Tax withholding | 4,714 | $79.86 | ↗ |
| Jul 30, 2026 | Apuli Maricel | Chief Accounting Officer | Disposed · Open-market sale | 2,000 | $80.06 | ↗ |
| Jul 9, 2026 | Ellis Andrea | director | Acquired · Option exercise | 17,167 | $16.75 | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of BridgeBio Pharma do institutions hold?
13F filers reported holding 54.8% of BridgeBio Pharma's shares as of Sep 30, 2026, across 351 filers.
How many 13F filers hold BridgeBio Pharma?
BridgeBio Pharma was held by 351 13F filers as of Sep 30, 2026.
Not investment advice.

